This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
by Ekta Bagri
Bristol Myers strengthens its Opdivo franchise with rising demand and strong uptake of Qvantig, leveraging label expansions to sustain revenue growth.
RHHBYPositive Net Change BMYNegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?
by Kanishka Das
Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.
IRWDNegative Net Change ABBVNegative Net Change PBYIPositive Net Change
biotechs medical
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
by Ahan Chakraborty
PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.
PFENo Net Change NVONegative Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy
by Zacks Equity Research
NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.
PFENo Net Change NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?
by Sundeep Ganoria
Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.
REGNNegative Net Change BEAMPositive Net Change NTLAPositive Net Change
biotechs cell-therapy crispr gene-editing gene-therapy medical pharmaceuticals
Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner
by Sundeep Ganoria
JAZZ leverages Epidiolex's rising sales and its broad drug portfolio to strengthen its position in the evolving medical cannabis market.
JAZZPositive Net Change TLRYNegative Net Change VRNONegative Net Change
biotechs marijuana medical pot-stocks
Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.
SNYNegative Net Change GILDPositive Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi
by Zacks Equity Research
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
BMYNegative Net Change JNJNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
by Zacks Equity Research
Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA patient group.
NVSPositive Net Change BAYRYPositive Net Change FOLDNegative Net Change RNAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
by Zacks Equity Research
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
SRPTNegative Net Change RNAPositive Net Change ARWRPositive Net Change PEPGNegative Net Change
biotechs gene-editing gene-therapy medical
NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies
by Zacks Equity Research
Novo Nordisk stock declines on the failure of two phase III studies evaluating oral Rybelsus for treating early-stage symptomatic AD.
NVONegative Net Change ADMANegative Net Change EDITNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
by Zacks Equity Research
BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
BIIBNegative Net Change ADMANegative Net Change EDITNegative Net Change ARQTNegative Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
by Ahan Chakraborty
Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally
by Sundeep Ganoria
LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.
PFENo Net Change NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?
by Kanishka Das
Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.
REGNNegative Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
by Zacks Equity Research
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
AZNPositive Net Change MRKPositive Net Change ADMANegative Net Change EDITNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
by Zacks Equity Research
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
NVSPositive Net Change BAYRYPositive Net Change FOLDNegative Net Change RNAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
by Sundeep Ganoria
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
REGNNegative Net Change ABBVNegative Net Change ANIPPositive Net Change
biotechs medical pharmaceuticals
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
by Ekta Bagri
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
BMYNegative Net Change JNJNegative Net Change PFENo Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
by Zacks Equity Research
Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.
ALKSNegative Net Change AGIONegative Net Change CRMDPositive Net Change FULCPositive Net Change
biotechs medical
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
by Zacks Equity Research
Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
ADMANegative Net Change EDITNegative Net Change COGTNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
by Zacks Equity Research
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
PFENo Net Change NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
by Zacks Equity Research
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
MRKPositive Net Change GILDPositive Net Change ADMANegative Net Change ARQTNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
by Zacks Equity Research
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
REGNNegative Net Change SNYNegative Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal
by Zacks Equity Research
Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deal's momentum.
ALKSNegative Net Change CRMDPositive Net Change AVDLPositive Net Change CSTLNegative Net Change
biotechs